Oncology and Zacks Investment Research

Selected news for the healthcare topic - Oncology, and the capital firm - Zacks Investment Research. We have 2,457 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised) | Nasdaq Nasdaq ... net product revenues of $1.325 billion to $1.425 billion.In January 2021, the FDA approved Cabometyx in combination with immuno-oncology drug Bristol-Myers‚Ao BMY Opdivo for the first-line treatment of patients with ... compared with the industry ‚Aos decline of 31%.Image Source: Zacks Investment ResearchThe company also outlined corporate priorities for 2022. It expects top-line results from COSMIC-313, the phase III study evaluating the ...
1/1/2022 Ikena Oncology (NASDAQ:IKNA) Shares Gap Up to $13.88 - WKRB News Ikena Oncology, Inc. (NASDAQ:IKNA) shares gapped up before the market opened on Thursday . The stock had previously closed at $13.88, but opened at $14.35. Ikena Oncology shares last traded at $13.93, with a volume of 210 shares.Several equities analysts have recently issued reports on the company. Zacks Investment Research lowered Ikena Oncology from a ‚Aubuy‚Au rating to a ‚Auhold‚Au rating in a report on Tuesday, November ...
12/23/2021 Elevation Oncology (NASDAQ:ELEV) Now Covered by Analysts at HC Wainwright Equities researchers at HC Wainwright began coverage on shares of Elevation Oncology (NASDAQ:ELEV) in a note issued to investors on Thursday, Briefing.com reports. The firm set a ‚Aubuy‚Au rating and a $12.00 price target on the stock. HC Wainwright‚Aos price objective suggests a potential upside of 144.90% from the company‚Aos previous close.Separately, Zacks Investment Research lowered shares of Elevation Oncology from a ‚Auhold‚Au rating ...
12/10/2021 Precigen (NASDAQ:PGEN) Lifted to Buy at Zacks Investment Research Zacks Investment Research upgraded shares of Precigen (NASDAQ:PGEN) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, Zacks.com reports. The brokerage currently has $4.00 target price on the biotechnology company‚Aos stock.According to Zacks, ‚AuPrecigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The ...
12/8/2021 Cardiff Oncology (NASDAQ:CRDF) Now Covered by Analysts at Robert W. Baird - Slater Sentinel Stock analysts at Robert W. Baird initiated coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a note issued to investors on Tuesday, The Fly reports. The firm set an ‚Auoutperform‚Au rating on the stock.Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Cardiff Oncology from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a research note on Wednesday, November ...
12/4/2021 Sierra Oncology, Inc. (NASDAQ:SRRA) Sees Large Decline in Short Interest Sierra Oncology, Inc. (NASDAQ:SRRA) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 46,800 shares, a decline of 27.2 ... an ‚Auoverweight‚Au rating in a report on Tuesday. Finally, Zacks Investment Research lowered Sierra Oncology from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a report on Saturday, November 13th.Shares of ...
10/19/2021 Recent Investment Analysts‚Äô Ratings Updates for Atara Biotherapeutics (ATRA) American Banking News ... Zacks Investment Research] from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating. According to Zacks, ‚AuAtara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company‚Aos lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential ...
10/19/2021 Trillium Therapeutics (NASDAQ:TRIL) Upgraded to ‚ÄúBuy‚Äù at Zacks Investment Research ... Zacks Investment Research from a ‚Ausell‚Au rating to a ‚Aubuy‚Au rating in a report released on Tuesday, Zacks.com reports. The brokerage currently has a $20.00 price target on the biotechnology company‚Aos stock. Zacks Investment Research ‚Aos target price would suggest a potential upside of 13.96% from the company‚Aos current price. According to Zacks, ‚AuTrillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies ...
10/16/2021 ALX Oncology (NASDAQ:ALXO) Downgraded by Zacks Investment Research to Hold Zacks Investment Research downgraded shares of ALX Oncology (NASDAQ:ALXO) from a buy rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, ‚AuALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company‚Aos product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California ...
10/13/2021 Salarius Pharmaceuticals (NASDAQ:SLRX) Upgraded to ‚ÄúHold‚Äù at Zacks Investment Research - The Cerbat Gem Zacks Investment Research upgraded shares of Salarius Pharmaceuticals (NASDAQ:SLRX) from a sell rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.According to Zacks, ‚AuSalarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company‚Aos lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid ...
10/9/2021 UroGen Pharma (NASDAQ:URGN) Downgraded by Zacks Investment Research UroGen Pharma (NASDAQ:URGN) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, ‚AuUroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company‚Aos product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform ...
10/9/2021 IMV (NASDAQ:IMV) Rating Increased to Buy at Zacks Investment Research - Stock Observer Zacks Investment Research upgraded shares of IMV (NASDAQ:IMV) from a hold rating to a buy rating in a research note released on Tuesday morning, Zacks.com reports. The brokerage currently has $2.00 target price on the stock.According to Zacks, ‚AuIMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune ...
10/7/2021 HUTCHMED (NASDAQ:HCM) Upgraded to ‚ÄúBuy‚Äù by Zacks Investment Research Dakota Financial News Zacks Investment Research upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have $38.00 target price on the stock. According to Zacks, ‚AuHutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is ...
10/7/2021 BridgeBio Pharma (NASDAQ:BBIO) Stock Rating Upgraded by Zacks Investment Research - Watch List News BridgeBio Pharma (NASDAQ:BBIO) was upgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Aubuy‚Au rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $53.00 ... genetic diseases. The Company‚Aos product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc ...
10/7/2021 Zacks Investment Research Lowers GT Biopharma (OTCMKTS:GTBP) to Hold Zacks Investment Research lowered shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a report released on Monday morning, Zacks.com reports. According to Zacks, ‚AuGT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is ...
10/7/2021 BridgeBio Pharma (NASDAQ:BBIO) Raised to ‚ÄúBuy‚Äù at Zacks Investment Research - The Cerbat Gem BridgeBio Pharma (NASDAQ:BBIO) was upgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Aubuy‚Au rating in a research note issued on Tuesday, Zacks.com reports. The brokerage currently has a $53.00 ... genetic diseases. The Company‚Aos product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc ...
10/7/2021 Zacks Investment Research Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Hold Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by Zacks Investment Research from a ‚Aubuy‚Au rating to a ‚Auhold‚Au rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, ‚AuCorvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist ...
10/7/2021 Zacks Investment Research Downgrades ADC Therapeutics (NYSE:ADCT) to Sell - Mayfield Recorder Mayfield Recorder ADC Therapeutics (NYSE:ADCT) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a note issued to investors on Tuesday, Zacks.com reports.According to Zacks, ‚AuADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in ...
10/7/2021 ADC Therapeutics (NYSE:ADCT) Stock Rating Lowered by Zacks Investment Research ADC Therapeutics (NYSE:ADCT) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, ‚AuADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland ...
10/7/2021 GT Biopharma (OTCMKTS:GTBP) Rating Lowered to Hold at Zacks Investment Research Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, ‚AuGT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International ...
10/7/2021 Aptevo Therapeutics (NASDAQ:APVO) Upgraded to Buy at Zacks Investment Research - The Cerbat Gem ... Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Aubuy‚Au rating in a report issued on Tuesday, Zacks.com reports. The firm currently has a $17.00 price target on the biotechnology company‚Aos stock. Zacks Investment Research ‚Aos price objective would indicate a potential upside of 18.96% from the stock‚Aos previous close.According to Zacks, ‚AuAptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and ...
10/7/2021 GT Biopharma (OTCMKTS:GTBP) Rating Lowered to Hold at Zacks Investment Research - Ticker Report Ticker Report Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a report released on Monday, Zacks.com reports.According to Zacks, ‚AuGT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based ...
10/7/2021 GT Biopharma (OTCMKTS:GTBP) Rating Lowered to Hold at Zacks Investment Research - Ticker Report Ticker Report Zacks Investment Research cut shares of GT Biopharma (OTCMKTS:GTBP) from a buy rating to a hold rating in a research note published on Monday morning, Zacks.com reports.According to Zacks, ‚AuGT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc ...
10/7/2021 Takeda Pharmaceutical (NYSE:TAK) Stock Rating Lowered by Zacks Investment Research - Transcript Daily Takeda Pharmaceutical (NYSE:TAK) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a note issued to investors on Tuesday, Zacks.com reports.According to Zacks, ‚AuTakeda Pharmaceutical ... resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare ...
10/7/2021 Takeda Pharmaceutical (NYSE:TAK) Downgraded by Zacks Investment Research to Sell - Stock Observer Takeda Pharmaceutical (NYSE:TAK) was downgraded by Zacks Investment Research from a ‚Auhold‚Au rating to a ‚Ausell‚Au rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.According to ... resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare ...